8 results about "Paroxysmal AF" patented technology

The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.

The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

Methods of treating paroxysmal nocturnal hemoglobinuria using MASP-3 serine protease inhibitors are provided. In some embodiments, the MASP-3 serine protease inhibitors are anti-MASP-3 antibodies. Also provided are uses of MASP-3 serine protease inhibitors in treatment of paroxysmal nocturnal hemoglobinuria, and for manufacture of a medicament for treatment of paroxysmal nocturnal hemoglobinuria.

Provided are systems and methods that may be employed to detect the presence or absence of paroxysmal nocturnal hemoglobinuria (PNH) in a subject that includes a leukocyte including GPI-anchors the leukocyte incubated with one or more blocking agents each independently specific to one or more GPI-anchored proteins, the leukocyte further incubated with a pro-aerolysin or derivative thereof, and optionally a second leukocyte including GPI-anchors not incubated with one or more of the blocking agents. The systems may be used as a positive control in assays detecting the presence or absence of PNH.

The present disclosure relates to stable aqueous solutions comprising high concentrations of an anti-C5 antibody (e.g., ravulizumab) and methods of making the solutions. The present disclosure also provides methods of using the solutions to treat or prevent complement-associated disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Therapeutic kits containing one or more of the solutions, and means for administering the solutions to a patient in need of such treatment, are also contemplated.

Disclosed are methods for cardioversion using bundanolol or a pharmaceutical composition comprising bundanolol for cardioversion of patients with paroxysmal or persistent AFib.

The present disclosure relates to the use of a Factor B inhibitor in the treatment of paroxysmal nocturnal hemoglobinuria. Specifically, the present disclosure relates to the use of the Factor B inhibitor or a pharmaceutically acceptable salt thereof in the preparation of a formulation for treating paroxysmal nocturnal hemoglobinuria (PNH) previously using a C5 complement inhibitor, wherein the Factor B inhibitor is represented by formula (I), (II) or (III).

Patients with paroxysmal or persistent atrial fibrillation whose untreated atrial fibrillation exceeds the threshold level are eligible for treatment with a drug that can control the patient's heart rhythm (e.g., budiodarone). Eligible patients are treated with the drug while their heart rate is monitored using a wearable device, and if a given drug dose is deemed ineffective, the dose is adjusted until an effective dose is determined for the patient or the patient is deemed unresponsive to the drug and is discontinued from treatment.